Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating FDA trial updates, product revenue splits, and manufacturing risk factors inside Vericel’s dense biotech disclosures can feel overwhelming. Each 10-K explains cell-expansion costs, while sudden 8-Ks reveal trial results that move the stock overnight. If you have ever typed “Vericel SEC filings explained simply” or searched for “Vericel insider trading Form 4 transactions,” you already know the challenge.
Stock Titan solves it. Our AI reads every Vericel annual report 10-K, quarterly earnings report 10-Q filing, and real-time Form 4 insider transactions, then distills the numbers and legal language into plain English. Need to understand Vericel proxy statement executive compensation or track a surprise shipment issue flagged in a Vericel 8-K material events explained section? One click delivers an annotated summary, key metrics, and trend graphics. Subscribers receive alerts the moment a Vericel Form 4 insider transactions real-time filing hits EDGAR, helping you gauge executive confidence before the market reacts.
All filings appear in a single dashboard—historical and current—so you can:
- Compare cartilage-implant sales across quarters without scrolling 200 pages
- Monitor Vericel executive stock transactions Form 4 alongside price charts
- Export AI-driven ratios that spotlight R&D spending swings
Vericel Corp (VCEL) insider Jonathan M. Hopper executed option-related transactions on 09/02/2025. Mr. Hopper exercised options with an $18 strike to acquire 10,000 shares and simultaneously sold 10,000 shares at $35.77 under an existing Rule 10b5-1 trading plan adopted May 30, 2025. After these transactions he beneficially owned 76,363 shares before the sale entry and 66,363 shares following the reported sale entry, reported as direct ownership. The reporting notes that some shares were acquired through the company’s 2015 Employee Stock Purchase Plan and that the underlying option grant (total right to buy 48,750 shares) vests in quarterly installments beginning May 11, 2020. The Form 4 was signed by an attorney-in-fact.
Form 144 filing for Vericel Corporation (VCEL) shows a planned sale of 10,000 common shares held by the reporting person through Fidelity Brokerage Services. The filing lists an approximate aggregate market value of $357,700 for the shares to be sold and indicates the shares represent part of an option granted on 02/11/2020 and acquired on 09/02/2025, with cash payment at exercise. The issuer's total shares outstanding are shown as 50,460,205, so the proposed block is a small fraction of the company. The filing also discloses a prior sale of 10,000 common shares by the same person on 06/02/2025 for $400,924. The notice affirms the signer does not possess undisclosed material adverse information.
Kevin F. McLaughlin, a director of Vericel Corporation (VCEL), exercised 7,000 stock options at an exercise price of $2.76 and immediately sold 7,000 common shares at $35.92 on 08/06/2025 pursuant to a Rule 10b5-1 trading plan adopted March 11, 2024.
After these transactions the filing reports beneficial ownership of 15,100 common shares. The filing also states the options originally granted on May 4, 2016 represented the right to purchase 15,000 shares and shows 0 derivative securities beneficially owned following the reported transactions.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
